What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%

Impact · against what's priced in

The news is moderately positive for Enliven Therapeutics as it confirms a strong capital runway and a clear path toward a critical Phase 3 trial. While the stock has surged 130%, the recent public offering provides the necessary funding to execute the ENABLE-2 trial without immediate dilution risk.

ELVN+0.40: No priced-in read yet
In context: The company has a substantial cash position of approximately $912 million (combined Q1 cash and recent offering) to fund operations into 2029 and launch the Phase 3 ENABLE-2 trial later this year.
Read from the article alone

What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%

clinical trials▲122%
biotech▲26%
pharmaceuticals
ELVN
cancer therapy
insider selling
oncology
sec filing

What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%

What matters in this story

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%

What matters in this story

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

How each ticker is affected

Track these names every morning.

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Where Will Neurocrine Biosciences Be in 5 Years?

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%

What matters in this story

Next reads from the same story arc

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%

What matters in this story

Next reads from the same story arc

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

How each ticker is affected

Track these names every morning.

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Where Will Neurocrine Biosciences Be in 5 Years?

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)